FY2025 Earnings Forecast for Pfizer Issued By Zacks Research

Pfizer Inc. (NYSE:PFE) – Investment analysts at Zacks Research upped their FY2025 EPS estimates for Pfizer in a research report issued to clients and investors on Tuesday, January 21st. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will earn $2.89 per share for the year, up from their previous estimate of $2.86. The consensus estimate for Pfizer’s current full-year earnings is $2.94 per share. Zacks Research also issued estimates for Pfizer’s Q4 2025 earnings at $0.85 EPS, Q3 2026 earnings at $0.88 EPS, Q4 2026 earnings at $0.86 EPS and FY2026 earnings at $3.00 EPS.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same period last year, the firm posted ($0.17) earnings per share. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year.

A number of other equities analysts have also recently issued reports on PFE. Wolfe Research assumed coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective on the stock. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Guggenheim dropped their target price on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $32.00.

Pfizer Trading Down 2.4 %

Shares of NYSE PFE opened at $26.01 on Thursday. The firm has a 50 day moving average price of $26.07 and a two-hundred day moving average price of $27.96. The stock has a market cap of $147.40 billion, a P/E ratio of 35.15, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Institutional Trading of Pfizer

A number of large investors have recently made changes to their positions in PFE. Wescott Financial Advisory Group LLC purchased a new position in shares of Pfizer during the 2nd quarter valued at about $224,000. Fred Alger Management LLC lifted its holdings in Pfizer by 6.6% during the second quarter. Fred Alger Management LLC now owns 95,592 shares of the biopharmaceutical company’s stock valued at $2,675,000 after purchasing an additional 5,932 shares in the last quarter. Point72 Europe London LLP bought a new position in shares of Pfizer in the second quarter worth approximately $3,698,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Pfizer in the second quarter worth $3,452,000. Finally, Caxton Associates LP bought a new stake in shares of Pfizer during the 2nd quarter valued at $738,000. 68.36% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.61%. Pfizer’s payout ratio is presently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.